Literature DB >> 1958051

Hormonal factors associated with weight loss in patients with advanced breast cancer.

M L Knapp1, S al-Sheibani, P G Riches, I W Hanham, R H Phillips.   

Abstract

Fasting blood samples were collected from 83 patients with histologically proven breast cancer and analysed for plasma glucagon, serum immunoreactive tumour necrosis factor (TNF alpha), insulin, glucose, growth hormone, cortisol and TSH. Samples from patients with known diabetes mellitus or thyroid disease, and those on parenteral nutrition or with evidence of infection were excluded as were patients who had a history of weight loss through dieting or who were anorexic. Fasting plasma glucagon, serum cortisol and immunoreactive TNF alpha concentrations in patients with stage IV breast cancer who had developed weight loss were significantly higher than those in patients with stage IV disease who had not developed weight loss. There were no significant differences in the fasting serum concentrations of insulin, glucose, growth hormone and TSH between the two patient groups. The association between weight loss in stage IV breast cancer and increased concentrations of plasma glucagon, serum cortisol and TNF alpha suggests a possible role for these hormonal factors in the development of cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1958051     DOI: 10.1177/000456329102800510

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  9 in total

1.  Metabolic effects of pioglitazone in chemically-induced mammary carcinogenesis in rats.

Authors:  Bianka Bojková; Miroslava Garajová; Martin Péč; Peter Kubatka; Karol Kajo; Marián Mokáň; Monika Kassayová; Peter Orendáš; Terézia Kisková; Eva Ahlersová; Ivan Ahlers
Journal:  Pathol Oncol Res       Date:  2011-06-07       Impact factor: 3.201

2.  Effect of glucagon on protein synthesis in human rectal cancer in situ.

Authors:  W H Hartl; H Demmelmair; K W Jauch; B Koletzko; F W Schildberg
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

3.  Expression of recombinant feline tumor necrosis factor is toxic to Escherichia coli.

Authors:  C M Otto; F Niagro; X Su; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

Review 4.  Clinical Implications of Sarcopenic Obesity in Cancer.

Authors:  Isabella P Carneiro; Vera C Mazurak; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

5.  The Newest Hypothesis about Vitiligo: Most of the Suggested Pathogeneses of Vitiligo Can Be Attributed to Lack of One Factor, Zinc-α2-Glycoprotein.

Authors:  Nooshin Bagherani
Journal:  ISRN Dermatol       Date:  2012-06-19

6.  The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia.

Authors:  S T Russell; M J Tisdale
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

7.  Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice.

Authors:  Andrea David Re Cecconi; Mara Barone; Mara Forti; Martina Lunardi; Alfredo Cagnotto; Mario Salmona; Davide Olivari; Lorena Zentilin; Andrea Resovi; Perla Persichitti; Dorina Belotti; Federica Palo; Nobuyuki Takakura; Hiroyasu Kidoya; Rosanna Piccirillo
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

8.  Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice.

Authors:  Agnès Martin; Josiane Castells; Valentine Allibert; Andréa Emerit; Cindy Zolotoff; Victoire Cardot-Ruffino; Yann S Gallot; Barbara Vernus; Véronique Chauvet; Laurent Bartholin; Laurent Schaeffer; Anne-Cécile Durieux; Christophe Hourdé; François B Favier; Laetitia Mazelin; Damien Freyssenet
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-11       Impact factor: 12.063

Review 9.  Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia.

Authors:  Maryam Ebadi; Vera C Mazurak
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.